Phase 2 study
Testing the safety and tolerability of Alogobat, administered as once-daily oral tablet.
Alogabat is a GABA-modulator which aims to restore GABA functioning which would improve symptoms and potentially aid brain development.
Participant Requirements
Below is a preliminary list of inclusion criteria.
See the full list of eligibility criteria on the clinical trials website.
- Clinical diagnosis of deletion genotype of Angelman syndrome
- Between 5 and 17 years old
- Able to undergo blood draws, ECG and EEG assessments
Locations
Chicago, IL
Rush Medical Center
Contact: Sara_A_Sandoval@rush.edu
New York, NY
Columbia University Medical Center
Carrboro, NC
Carolina Institute for Development Disabilities University of North Carolina/School of Medicine
Contact: victoria_banks@neurology.unc.edu
Bedford Park, Australia, South Australia
Flinders Medical Centre Recruiting
Marseille, France
Hopital la Timone Enfants; Service de Pediatrie et Neurologie Pediatrique
Paris, France
Groupe Hospitalier Necker Enfants Malades
Roma, Lazio, Italy
Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione
Genova, Liguria, Italy
IRCCS Istituto G. Gaslini; UOC Neurologia Pediatrica e Malattie Muscolari
Sabadell, Barcelona, Spain
Corporacio Sanitaria Parc Tauli
More Information and Screening Enrollment
Find more information on the Roche website.
More details on clinicaltrials.gov
Questions about this study and enrollment interest can be directed to:
888-662-6728 (US and Canada) or global-roche-genentech-trials@gene.com
Reference Study ID Number: BP41315